BERINERT 1500 KIT

国家: 加拿大

语言: 英文

来源: Health Canada

有效成分:

C1 ESTERASE INHIBITOR (HUMAN)

可用日期:

CSL BEHRING CANADA INC

ATC代码:

B06AC01

INN（国际名称）:

C1-INHIBITOR, PLASMA DERIVED

剂量:

1500UNIT

药物剂型:

KIT

组成:

C1 ESTERASE INHIBITOR (HUMAN) 1500UNIT

给药途径:

INTRAVENOUS

每包单位数:

3ML

处方类型:

Schedule D

治疗领域:

COMPLEMENT INHIBITORS

產品總結:

Active ingredient group (AIG) number: 0152746002; AHFS:

授权状态:

APPROVED

授权日期:

2014-12-23

产品特点

Page 1 of 45
PRODUCT MONOGRAPH
BERINERT
® 500 / BERINERT
® 1500
C1 ESTERASE INHIBITOR, HUMAN
Powder and Diluent for Solution for Injection
For Intravenous Administration
500 IU/vial, reconstituted with 10 mL of diluent
1500 IU/vial, reconstituted with 3 mL of diluent
CSL Behring Canada, Inc.
55 Metcalfe Street, Suite 1460
Ottawa, Ontario
K1P 6L5
Date of Initial Approval: May 31, 2010
Date of Revision: February 14, 2020
Submission Control No: 235563
Page 2 of 45
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
DESCRIPTION...................................................................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
..................................................................................................
4
ADVERSE REACTIONS
...................................................................................................
6
DRUG INTERACTIONS
.................................................................................................
12
DOSAGE AND ADMINISTRATION
.............................................................................
12
OVERDOSAGE
...............................................................................................................
15
ACTION AND CLINICAL PHARMACOLOGY
........................................................... 15
STORAGE AND STABILITY
.........................................................................................
18
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 18
PART II: SCIENTIFIC INFORMATION
..............................................................................
19
PHARMACEUTICAL INFORMATION
.........................................................................
19
CLINICAL TRIAL